Rachel Rogers, PharmD

Director
Gilead Sciences, Inc.

Poster(s):

• (249) Tenofovir alafenamide versus non-tenofovir alafenamide-containing antiretroviral regimens and the effects on changes of proteinuria biomarkers in the treatment of human immunodeficiency virus type 1: a systematic literature review and meta-analysis
  Wednesday, October 29, 2025